| Literature DB >> 31915506 |
Yanfei Liu1,2, Weiliang Weng2, Rui Gao2, Yue Liu3.
Abstract
Aging is a progressive disease affecting around 900 million people worldwide, and in recent years, the mechanism of aging and aging-related diseases has been well studied. Treatments for aging-related diseases have also made progress. For the long-term treatment of aging-related diseases, herbal medicine is particularly suitable for drug discovery. In this review, we discuss cellular and molecular mechanisms of aging and aging-related diseases, including oxidative stress, inflammatory response, autophagy and exosome interactions, mitochondrial injury, and telomerase damage, and summarize commonly used herbals and compounds concerned with the development of aging-related diseases, including Ginkgo biloba, ginseng, Panax notoginseng, Radix astragali, Lycium barbarum, Rhodiola rosea, Angelica sinensis, Ligusticum chuanxiong, resveratrol, curcumin, and flavonoids. We also summarize key randomized controlled trials of herbal medicine for aging-related diseases during the past ten years. Adverse reactions of herbs were also described. It is expected to provide new insights for slowing aging and treating aging-related diseases with herbal medicine.Entities:
Mesh:
Year: 2019 PMID: 31915506 PMCID: PMC6930799 DOI: 10.1155/2019/4598167
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1Epidemiological trends of aging worldwide.
Figure 2Main aging-related diseases with age and incidence.
MicroRNAs involved in aging-related diseases.
| miR type | Model | Function | Target gene | Reference |
|---|---|---|---|---|
| miR-17 | H2O2 induced senescent cells | Inhibited mTOR and JNK activation | ADCY5, ISR1 | [ |
| miR-83 | Caenorhabditis elegans | Inhibitory activity of miR-83 | din-1, daf-16 | [ |
| miR-29 | Senescent embryonic fibroblast cell | Mediated loss of H4K20me3 promotes senescence | Suv4-20h2 | [ |
| miR-1292 | hADSCs | Accelerated hADSC senescence and restrained osteogenesis | FZD4 | [ |
| miR-335-3p | Male C57B/6J mice | Reduced cholesterol and impaired memory | Cholesterol | [ |
| miR-195 | Neonatal mouse cardiomyocyte | Promote apoptosis, causing lipotoxic cardiomyopathy | SIRT1 | [ |
| miR-126 | HUVECs | Regulate high-fat diet-induced endothelial permeability and apoptosis | TGF- | [ |
| miR-138 | Aging participants | Regulating the memory function of the elderly | DCP1B | [ |
| miR-451 | Streptozotocin-induced diabetic mouse heart | Participated in cardiac fibrosis | TGF- | [ |
| miR-34 | Myocardial infarction (MI) in neonatal and adult mice | Its inhibition diminished cell apoptosis | Bcl2, cyclin D1, Sirt1 | [ |
| miR-146a | Human microvascular endothelial cells (HMVECs) | Ameliorates endothelial inflammation and the progression of atherosclerosis | Receptor-associated factor 6 (TRAF6) | [ |
| miR-21 | Human umbilical vein ECs | Promoting endothelial inflammation | PPAR | [ |
| miR-155 | Human nasopharyngeal cancer and cervical cancer cells | Prevention of an age-induced deleterious decrease in autophagy | RHEB, RICTOR, RPS6KB2 | [ |
| miR-24 | H9C2 cardiomyocytes | Attenuate cardiomyocyte apoptosis and myocardial injury | Keap1 | [ |
| miR-181 | Apolipoprotein E-deficient mice | Dampen the inflammatory response in the endothelium | NF- | [ |
| miR-18a | Naturally aged mice | Regulation of extracellular matrix production during aging cardiomyopathy | CTGF, TSP-1 | [ |
| miR-377 | Old skin tissues | Promotes fibroblast senescence | DNA methyltransferase 1 (DNMT1) | [ |
| miR-9-5p | Human neuroblastoma cell line SH-SY5Y | Suppression in cell apoptosis, inflammation, and oxidative stress | SIRT1 | [ |
| miR-124 | Normal human epidermal keratinocytes | Cause skin cell senescence | MEK1, cyclin E1 | [ |
| miR-15 | Human dermal fibroblast | Counteracting senescence-associated mitochondrial dysfunction | SIRT4 | [ |
Figure 3Chemical structural formula of the main active ingredients of herbs and compounds.
Figure 4Possible mechanism of herbal medicines in slowing aging.
Figure 5Possible mechanisms of aging and aging-related diseases.
Preclinical studies of herbal medicine for aging-related diseases.
| Active ingredients | Dosage | Administration | Model | Possible mechanism | Reference |
|---|---|---|---|---|---|
| In vitro studies | |||||
| EGb | 10, 25, and 50 mg/L | Pretreatment for 24 h | EPCs cultured on fibronectin-coatedculture dishes | Activation of telomerase through the PI3k/Akt signaling pathway | [ |
| Ginsenoside Rg1 | 10 | Cultured for 6 h | Aging Sca-1+ hematopoietic cells | Regulating the p16-Rb signaling pathway, repairing worn telomeres, and maintaining telomerase activity | [ |
| PNS | 5, 25, and 50 | Pretreatment for 4 h | D-Galactose induced aging H9c2 cells | Increase antioxidant capacity and reduce apoptosis | [ |
| Astragalus membranaceus | 100, 200, 400, and 600 | Pretreatment for 24 h | Cardiomyocyte model of oxidative stress | Attenuating the oxidative injury and arresting the influx of Ca2+ to block cell death | [ |
| Lycium barbarum | 15, 30, and 60 | Pretreatment for 24 h | Primary hippocampal neurons | Activating the PI3K/Akt/mTOR signaling pathway | [ |
| Angelica sinensis | — | — | Aging hematopoietic stem cells | Increase in the length of telomere and the activity of telomerase, downregulation of the expression of P53 protein | [ |
| Ligustrazine | 50, 100, and 200 | Pretreated for 24 h | Hypoxia-induced injury of HUVECs | Upregulation of miR-135b and subsequent activation of JNK/SAPK and PI3K/AKT/mTOR pathways | [ |
| Gynostemma pentaphyllum extract | 0.5-5.0 mg/mL | — | Mouse dermal fibroblasts induced oxidative stress | Reduce oxidative stress | [ |
| Resveratrol | 5, 10, and 50 | Cultured for 24 h | H2O2 induced aging of HUVECs | Upregulation of autophagy | [ |
| Curcumin | 1, 5, 10, and 20 | Treatment for 48 h | Rat adipose tissue-derived stem cells | Promoting TERT gene expression | [ |
|
| |||||
| In vivo studies | |||||
| EGb-761 | 20,40, 80, and 100 mg/kg | i.g. every 3 days, for 12 months | Aged mice (24 months) of middle cerebral artery occlusion | Upregulation of phosphatase PP2A and diminished extracellular signal-regulated kinase (ERK) activation | [ |
| EGb | 200, 400 mg/kg/day | i.g. 12 weeks | Streptozotocin-induced diabetic ApoE−/− mice | Inhibiting endoplasmic reticulum stress via restoration of autophagy through the mTOR signaling pathway | [ |
| Ginsenoside Rg1 | 20 mg/kg/day | i.p. 28 days | D-Galactose-induced aging mice | Antioxidation and downregulation of the p19/p53/p21 signaling pathway | [ |
| Panax notoginseng saponins | 10, 30, and 60 mg/kg/day | i.g. 6 months | Natural aging rats | Attenuating oxidative damage | [ |
| Astragalus membranaceus | 100, 200, 400, and 600 mg/kg | i.g. twice per day for 7 times | Rat model of persistent myocardial ischemia | Reducing oxidative damage and free radical generation | [ |
| Astragalosides | 8, 16, and 32 mg/kg | i.g. 14 days | Rats with learning and memory impairment | Downregulate the mRNA levels of APP and | [ |
| Astragalus polysaccharides | 100, 200, and 300 mg/kg/d | i.g. 7 weeks | D-Galactose induced aging mice | Scavenging ROS, inhibiting mitochondrial PT, and increasing the activities of antioxidases | [ |
| Lycium barbarum | 0.5 or 2.0 g/kg | i.g. 4 weeks | A mouse model of AD induced by the combination of AlCl3 and D-galactose | Modulation of the mitochondrial pathway of apoptosis and the cholinergic system | [ |
| Goji berry | 150, 300 mg/kg | i.g. 6 weeks | Natural aging rats | Antioxidative stress | [ |
| Rhodiola rosea | 60, 120 mg/kg | i.g. 9 weeks | Abdominal aorta of atherosclerosis rats | Hypolipemic, antioxidant, and anti-inflammatory activities | [ |
| Angelica polysaccharide | 140 mg/kg | i.p. 27 days | Aging nestin-GFP mice induced by D-galactose | Enhancing the antioxidant and anti-inflammatory capacity, upregulation of p53/p21 signaling pathway | [ |
| Tetramethylpyrazine | 1, 3, and 10 mg/kg | i.p. 7 or 14 days | 6-OHDA-induced Parkinson's disease mice | Activation of PI3K/Akt/GSK3 | [ |
| Resveratrol | 30, 100 mg/kg/d | i.g. 2 weeks | Mice with chemotherapy-induced ovarian aging | Attenuating oxidative stress injury by activating Nrf2 | [ |
| Curcumin | 100, 200, and 400 mg/kg/d | i.g. 6 months | Natural aging rats | Suppressing age-related changes in inflammatory indices | [ |
| Baicalein | 10, 30 mg/kg/day | i.p. 7 days | MPP+-induced Parkinson's disease mice | Inhibit inflammatory activities and MPP+-induced apoptosis and autophagy | [ |
Abbreviations: EGb: Ginkgo biloba extract; EPCs: endothelial progenitor cells; HUVECs: human umbilical endothelial vein cells; i.g.: intragastric gavage; i.p.: intraperitoneally injected.
Published randomized controlled trials of herbal medicines for the treatment of aging-related diseases in humans.
| Number | Authors (year) | Targets | Conditions | Age (years) | Name of herb or formula | Dose/duration | Groups | Main outcomes | Adverse reactions |
|---|---|---|---|---|---|---|---|---|---|
| (1) | Liu et al. (2007) [ |
| Aging vascular dementia | ≥55 | Kangxin capsule ( | 0.9 g once and three times per day, for 1 month | I: compound | CD4, CD4, CD8−1 ↑ ( | No adverse reactions were observed |
| (2) | Zhao et al. (2018) [ |
| Type 2 diabetes mellitus | 50-75 | Ginkgo leaf tablets | 2 Ginkgo leaf tablets and 8 Liuwei Dihuang pills, 3 times a day, for 36 months | I: compound | Plasma CML, 8-IsoP levels ↓ ( | Drug reaction |
| (3) | Kwok et al. (2014) [ |
| Atherosclerosis in postmenopausal | 56.0 ± 3.8 | DG capsules (Danshen and ginseng) | Two capsules daily, for 12 months | I: compound | TC, LDL-C carotid IMT ↓ ( | No adverse reactions were observed |
| (4) | Dingzhu et al. (2015) [ |
| Carotid atherosclerosis | 57.7 ± 4.4 | Shoushen granule ( | 1 tablet once daily for 24 weeks | I: compound | baPWV, IMTEp, AI, PWV | Not reported |
| (5) | Lv et al. (2016) [ |
| Type 2 diabetes mellitus | 50-80 | Naoxintong ( | 1.2 g per day for 3 months | I: compound | HbA1c ↓ ( | Not reported |
| (6) | Akhondzadeh et al. (2003) [ |
| Alzheimer's disease | 65-80 | Salvia officinalis extract | 60 drops daily for 16 weeks | I: compound | ADAS-cog, CDR-SB ↓ ( | Vomiting, wheezing, nausea |
| (7) | Akhondzade et al. (2010) [ |
| Alzheimer's disease | 72.65 ± 3.89 | Saffron | 15 mg twice per day, for 16 weeks | I: compound | ADAS-cog, CDR-SB ↓ ( | Dry mouth |
| (8) | Jia et al. (2014) [ |
| Vascular dementia | 64.9 ± 9.1 | SaiLuoTong (Ginkgo biloba, ginsenosides, saffron) | 360/240 mg daily, for 52 weeks | I: compound | VaD Assessment Scale—cognitive subscale scores ( | Mild gastrointestinal intolerance, abnormal alanine aminotransferase, dreaminess |
| (9) | Tajadini et al. (2015) [ |
| Alzheimer's disease | >50 | Davaie Loban | 500 mg, three times daily, for 3 months | I: compound | ADAS-cog, CDR-SB ↓ ( | Without any adverse drug reaction |
| (10) | Uno et al. (2005) [ |
| Type 2 diabetes | 64 ± 1 | Goshajinkigan | 7.5 g daily for 1 month | I: combined compound and OHAs | HOMA-R, FBG TC, TG ↓ ( | No adverse reactions were observed |
| (11) | Cho et al. (2009) [ |
| Healthy female | 53.6 ± 7.4 | Red ginseng root extract mixed with Torilus fructus and Corni fructus | 3 g daily for 24 weeks | I: compound | Facial wrinkles ↓ | Gastrointestinal discomfort |
Abbreviations: GDS: Geriatric Depression Scale; HIS: Hachinski Ischemia Scale; ET: endothelin; E2·T−1: estradiol (E2)·testosterone (T)−1; CML: carboxymethyl lysine; 8-IsoP: 8-isoprostane; FBG: fasting blood glucose; PBG: postprandial blood glucose; HbA1c: glycosylated hemoglobin; TC: total cholesterol; TG: triglyceride; HDL: high-density lipoprotein; LDL: low-density lipoprotein; IMT: intima-media thickness; GLU: glucose; Ep: pressure-strain elastic modulus; Ac: arterial compliance; AI: augmentation index; PWVβ: pulse wave velocity β; HUVECs: human umbilical vein endothelial cells; ADAS-cog: cognitive subscale of Alzheimer's Disease Assessment Scale; CDR: Clinical Dementia Rating; OHAs: oral hypoglycemic agents.